BSN 246 HESI Health Assessment Exam – 150-
Question Comprehensive Practice Exam (V1 & V2
Package)
Section I: Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics (1–25)
1. A nurse practitioner is reviewing the process by which a drug moves from the site of
administration into the bloodstream. This process is known as:
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B
Rationale: Absorption is the movement of a drug from its site of administration into the
systemic circulation. Distribution follows absorption; metabolism and excretion are elimination
processes.
2. Which of the following routes of administration has 100% bioavailability?
A. Oral
B. Intramuscular
C. Intravenous
D. Subcutaneous
Correct Answer: C
Rationale: Intravenous administration bypasses absorption barriers, delivering the drug
directly into the systemic circulation with 100% bioavailability.
3. The first-pass effect primarily affects drugs administered by which route?
A. Intravenous
B. Oral
C. Sublingual
D. Transdermal
, Correct Answer: B
Rationale: Orally administered drugs are absorbed through the GI tract and pass through
the liver via the portal vein, where they may be extensively metabolized before reaching
systemic circulation.
4. A drug with a narrow therapeutic index requires:
A. No monitoring
B. Therapeutic drug monitoring
C. Higher doses
D. Less frequent dosing
Correct Answer: B
Rationale: Drugs with a narrow therapeutic index have a small margin between therapeutic
and toxic effects, requiring close monitoring of serum levels.
5. Which pharmacokinetic parameter reflects the time required for the drug concentration to
decrease by 50%?
A. Onset
B. Peak
C. Half-life
D. Duration
Correct Answer: C
Rationale: Half-life is the time required for the plasma concentration of a drug to decrease
by 50%.
6. A drug that binds to a receptor and produces a maximal response is called a:
A. Partial agonist
B. Antagonist
C. Full agonist
D. Inverse agonist
Correct Answer: C
Rationale: A full agonist binds to and fully activates a receptor, producing a maximal
response.
,7. A competitive antagonist:
A. Permanently binds the receptor
B. Can be overcome by increasing agonist concentration
C. Produces a maximal response
D. Increases receptor sensitivity
Correct Answer: B
Rationale: Competitive antagonists bind reversibly and can be displaced by higher
concentrations of the agonist.
8. Which CYP450 enzyme is responsible for metabolizing the majority of drugs?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
Correct Answer: C
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, making it the most clinically
significant CYP enzyme.
9. A patient with a genetic polymorphism resulting in poor CYP2D6 metabolism is at increased
risk for:
A. Decreased drug effect
B. Increased drug toxicity
C. No change in drug effect
D. Faster drug elimination
Correct Answer: B
Rationale: Poor metabolizers cannot efficiently metabolize drugs via CYP2D6, leading to
drug accumulation and increased risk of toxicity.
10. A prodrug requires:
A. No metabolism
B. Activation via metabolism
C. Renal excretion
D. Protein binding
, Correct Answer: B
Rationale: Prodrugs are inactive and require metabolic conversion to their active form.
11. Which of the following is a pharmacodynamic concept?
A. Absorption
B. Distribution
C. Receptor interaction
D. Excretion
Correct Answer: C
Rationale: Pharmacodynamics refers to the effects of drugs on the body, including receptor
interactions.
12. Loading dose is calculated based on:
A. Volume of distribution
B. Clearance
C. Half-life
D. Bioavailability only
Correct Answer: A
Rationale: Loading dose is determined by volume of distribution and desired plasma
concentration.
13. Which factor most significantly affects drug distribution in the elderly?
A. Increased body water
B. Decreased body fat
C. Decreased total body water and increased fat
D. Increased lean muscle mass
Correct Answer: C
Rationale: Elderly clients have decreased total body water and increased fat, altering drug
distribution; lipophilic drugs have larger volumes of distribution.
14. A patient with chronic kidney disease requires careful dosing because of:
Question Comprehensive Practice Exam (V1 & V2
Package)
Section I: Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics (1–25)
1. A nurse practitioner is reviewing the process by which a drug moves from the site of
administration into the bloodstream. This process is known as:
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B
Rationale: Absorption is the movement of a drug from its site of administration into the
systemic circulation. Distribution follows absorption; metabolism and excretion are elimination
processes.
2. Which of the following routes of administration has 100% bioavailability?
A. Oral
B. Intramuscular
C. Intravenous
D. Subcutaneous
Correct Answer: C
Rationale: Intravenous administration bypasses absorption barriers, delivering the drug
directly into the systemic circulation with 100% bioavailability.
3. The first-pass effect primarily affects drugs administered by which route?
A. Intravenous
B. Oral
C. Sublingual
D. Transdermal
, Correct Answer: B
Rationale: Orally administered drugs are absorbed through the GI tract and pass through
the liver via the portal vein, where they may be extensively metabolized before reaching
systemic circulation.
4. A drug with a narrow therapeutic index requires:
A. No monitoring
B. Therapeutic drug monitoring
C. Higher doses
D. Less frequent dosing
Correct Answer: B
Rationale: Drugs with a narrow therapeutic index have a small margin between therapeutic
and toxic effects, requiring close monitoring of serum levels.
5. Which pharmacokinetic parameter reflects the time required for the drug concentration to
decrease by 50%?
A. Onset
B. Peak
C. Half-life
D. Duration
Correct Answer: C
Rationale: Half-life is the time required for the plasma concentration of a drug to decrease
by 50%.
6. A drug that binds to a receptor and produces a maximal response is called a:
A. Partial agonist
B. Antagonist
C. Full agonist
D. Inverse agonist
Correct Answer: C
Rationale: A full agonist binds to and fully activates a receptor, producing a maximal
response.
,7. A competitive antagonist:
A. Permanently binds the receptor
B. Can be overcome by increasing agonist concentration
C. Produces a maximal response
D. Increases receptor sensitivity
Correct Answer: B
Rationale: Competitive antagonists bind reversibly and can be displaced by higher
concentrations of the agonist.
8. Which CYP450 enzyme is responsible for metabolizing the majority of drugs?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9
Correct Answer: C
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, making it the most clinically
significant CYP enzyme.
9. A patient with a genetic polymorphism resulting in poor CYP2D6 metabolism is at increased
risk for:
A. Decreased drug effect
B. Increased drug toxicity
C. No change in drug effect
D. Faster drug elimination
Correct Answer: B
Rationale: Poor metabolizers cannot efficiently metabolize drugs via CYP2D6, leading to
drug accumulation and increased risk of toxicity.
10. A prodrug requires:
A. No metabolism
B. Activation via metabolism
C. Renal excretion
D. Protein binding
, Correct Answer: B
Rationale: Prodrugs are inactive and require metabolic conversion to their active form.
11. Which of the following is a pharmacodynamic concept?
A. Absorption
B. Distribution
C. Receptor interaction
D. Excretion
Correct Answer: C
Rationale: Pharmacodynamics refers to the effects of drugs on the body, including receptor
interactions.
12. Loading dose is calculated based on:
A. Volume of distribution
B. Clearance
C. Half-life
D. Bioavailability only
Correct Answer: A
Rationale: Loading dose is determined by volume of distribution and desired plasma
concentration.
13. Which factor most significantly affects drug distribution in the elderly?
A. Increased body water
B. Decreased body fat
C. Decreased total body water and increased fat
D. Increased lean muscle mass
Correct Answer: C
Rationale: Elderly clients have decreased total body water and increased fat, altering drug
distribution; lipophilic drugs have larger volumes of distribution.
14. A patient with chronic kidney disease requires careful dosing because of:
